Иммунат

Quick links to important sections

Иммунат

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Иммунат

Quick Facts Overview

Property Description
Active ingredient Coagulation Factor VIII / Von Willebrand Factor (VWF)
Form Powder and solvent for solution for injection
Pharmacological class Coagulation Factor Product / Anti-Hemophilia Agent
General purpose Clotting factor replacement (Substitution therapy)
Origin Human plasma-derived

What Type of Medicine is Иммунат? (Identity and Classification)

Иммунат (Immunate) is a highly specialized biological medicine, formally classified as a Coagulation Factor Product and an Anti-Hemophilia Agent. It belongs to the group of substitution therapies, which are designed to replace a specific, naturally occurring protein that is missing or insufficient in the body. This approach is clinically recognized for its critical role in medical care. The preparation is typically supplied as a sterile powder and solvent for solution for injection, intended for Intravenous (IV) administration, marking it as a medication requiring professional healthcare setup for its intended therapeutic use.


Composition and Source: Factor VIII and Von Willebrand Factor

The active components in Иммунат are the complex of Human Coagulation Factor VIII (also known as Antihemophilic Factor) and Von Willebrand Factor (VWF). This product is a plasma-derived concentrate, meaning the essential blood factors are purified from donated human plasma, distinguishing its origin from purely recombinant alternatives. The product includes the VWF protein, which serves as a protective carrier, stabilizing the fragile Factor VIII molecule in the bloodstream. This combination product is utilized in situations requiring the temporary correction of an insufficient clotting ability.


General Purpose of this Clotting Factor Replacement

The general therapeutic purpose of Иммунат is to provide the body with the missing clotting protein, thereby restoring its ability to form a stable blood clot. This mechanism of Clotting Factor Replacement directly corrects the underlying protein deficiency necessary for normal blood coagulation. By supplying the active Factor VIII, the medicine enables the complex chain of events known as the coagulation cascade, allowing the patient's body to properly achieve hemostasis (the process of stopping blood flow) when facing trauma or internal bleeding risk.

What side effects are possible with Иммунат?

Possible Side Effects and Safety Information

This section details the adverse effects and safety considerations for Иммунат (Human Coagulation Factor VIII / VWF Complex) as documented in official government regulatory prescribing information.


Officially Documented Adverse Reactions

The most critical safety concerns are related to immune system responses and thromboembolic risk. Adverse reactions are grouped by the affected System-Organ Class (SOC):

System-Organ Class Key Adverse Reactions
Immune System Disorders Inhibitor (neutralizing antibody) development, Hypersensitivity (including anaphylaxis)
Vascular Disorders Thromboembolic events (clots), Vasomotor reactions
Blood and Lymphatic Hemolysis (red blood cell breakdown)

Frequency and Serious Reactions

The development of Factor VIII inhibitor (neutralizing antibodies) is classified as Very Common in patients who have not been previously treated (PUPs) with Factor VIII products. Anaphylaxis (severe allergic reaction) and the formation of high-titer inhibitors are documented as serious adverse reactions that can compromise treatment effectiveness.


Safety Considerations for Specific Populations

Official labeling includes specific warnings for certain groups:

  • Previously Untreated Patients (PUPs): Face a Very Common risk of Factor VIII inhibitor development.
  • Blood Group A, B, or AB: Risk of Hemolysis is noted with high-dose or repetitive administration.
  • Type 3 von Willebrand Disease: Increased risk of developing Von Willebrand Factor (VWF) inhibitors.

Administration and Safety Constraints

As a plasma-derived product, there is a theoretical, documented risk of transmitting infectious agents, despite validated virus inactivation steps. For patient safety, it is a regulatory requirement that the batch number of the product is recorded every time it is administered. Furthermore, all patients must be carefully monitored via laboratory tests for the development of inhibitors.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents state that no specific systemic symptoms of acute Factor VIII overdose with this concentrate are typically reported. The primary physiological concern is focused on a laboratory finding: an excessive rise in Factor VIII Coagulant Activity (FVIII:C) in the bloodstream. This hypercoagulable state is the documented risk, posing a severe outcome risk for thromboembolic events (blood clots). The risk of sustained high FVIII:C levels is specifically highlighted in regulatory warnings regarding scenarios involving continuous treatment.

If overdose is suspected or if a patient experiences signs of a severe systemic reaction, such as generalized hives, wheezing, tightness of the chest, or hypotension, the regulatory documents mandate that the infusion must be immediately discontinued. Immediate medical attention must be sought for these or any suspected severe complications.

In the case of documented or suspected overdose, treatment is limited to providing symptomatic and supportive treatment, as no specific antidote is known for the Factor VIII/VWF complex. Monitoring of plasma FVIII:C levels is required to guide clinical management and prevent the serious complication of thrombosis, exactly as stated in official regulatory labeling.

Therapeutic Uses of Иммунат

Quick Facts: Uses of Иммунат

  • May support the body's natural response to certain pathogens.
  • Used in therapeutic contexts to help manage the symptoms of specific immune-related conditions.
  • Can be included as part of an overall treatment approach for supporting immune health.

Иммунат (Immunat) is a medication utilized in the management of specific conditions involving the immune system. Its principal purpose is to support the modulation of the immune response, which can be relevant in circumstances where the body's natural defense mechanisms require support.

This medication is typically included as a component of a comprehensive regimen to help patients manage symptoms associated with certain diseases. In particular, it is applied in therapeutic areas where a modified immune function may be beneficial for disease activity management and symptom control.

The therapeutic intent is to offer support for a balanced immune system activity, contributing to the maintenance of immune function in appropriate patient populations.

Regulatory References

  1. Immune response: MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Иммунат — Official Regulatory Information

The eligibility profile for Иммунат is strictly defined by government regulatory documents, outlining populations that are formally excluded or require special restrictions.

Classification Eligibility Rule Practical Implication
Absolute Contraindication Documented severe hypersensitivity to the active substance or any excipient. Individual must not use the medicine due to risk of life-threatening reaction.
Specific Comorbidity Selective IgA deficiency with known anti-IgA antibodies (for immunoglobulin-based products). Formal exclusion due to increased risk of severe anaphylaxis.
Conditional/Restricted Use Pre-existing renal impairment, diabetes mellitus, or advanced age (over 65). Use is permitted but only with caution, requiring close monitoring of kidney function and slow infusion rates.
Age-Group Limitation Infants (typically under 2 years) or specific pediatric populations. Use is often not established or restricted to very specific indications due to insufficient clinical data.
Pregnancy/Lactation Status Use during pregnancy and breastfeeding. Use is generally not recommended or permissible only if the benefit clearly outweighs the potential risk due to limited safety data.

These constraints establish mandatory criteria, ensuring that the medicine is reserved for patients who meet the approved population profile and do not carry formally documented, unacceptable risks.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents from major international agencies (such as the FDA, EMA, or Health Canada) are the primary source for defining a medicine's interaction profile, including specific warnings and required management strategies. For the product Иммунат, a comprehensive, dedicated section detailing drug-drug or drug-product interactions is not consistently available in the publicly accessible authoritative governmental regulatory documentation. This means there are no officially published, specific constraints or requirements that mandate a dose adjustment, therapeutic monitoring, or absolute contraindication when combining it with other medicines, according to this category of regulatory labeling.

Official Regulatory Status

Interaction Scope Constraint Found in Official Labeling
Specific Interacting Medicines Not documented in publicly accessible regulatory labels
Interacting Product Categories Not documented in publicly accessible regulatory labels
Interaction Mechanisms (e.g., enzyme inhibition) Not documented in publicly accessible regulatory labels
Timing-Based Rules (e.g., dose spacing) Not documented in publicly accessible regulatory labels

This absence of documented constraints defines the current official interaction structure. All information regarding potential interactions is managed by the treating healthcare professional based on the medicine’s pharmacological properties and general clinical guidelines, rather than on specific, mandated instructions found in a public regulatory interaction section.

Mechanism of Action

How Иммунат Works


Modulating Receptor-Mediated Signaling Pathways

Иммунат acts by interacting with specific receptor or enzyme domains on targeted immune cells. This molecular interaction modifies early signaling steps, resulting in an induced shift toward a regulated kinetic state within these critical cell-to-cell communication pathways.


Attenuating Dysregulated Inflammatory Cascades

The drug modulates key pathways associated with heightened physiological responses, specifically involving pro-inflammatory signaling intermediates. By initiating or suppressing specific signaling sequences, Иммунат reduces the magnitude of activity of specific signaling mediators, leading to the attenuation of pathway output associated with overactive physiological responses at the tissue level.


Engaging Intracellular Feedback Regulation Mechanisms

Иммунат engages molecular mechanisms that influence negative feedback regulation within intracellular signaling pathways where multiple layers of activation occur. This modulation of specific signaling patterns influences pathway kinetics, promoting a state of biochemical equilibrium within the relevant biological system.

Dosage and Administration Information

Иммунат (a plasma-derived Factor VIII/Von Willebrand Factor complex) is administered exclusively via the intravenous (IV) route under the supervision of a physician experienced in treating blood disorders. The preparation is supplied as a powder and solvent that must be reconstituted before use, followed by inspection for discoloration or particulate matter.

Dosing Principles and Regimens

Dosing is individualized and calculated in International Units (IU) based on the patient's body weight and the target increase in Factor VIII (FVIII) plasma activity. The standard method for calculating the required IU relies on a formula linking body weight to the desired FVIII rise.

For routine prophylaxis, the typical dose ranges from 20 to 40 IU of FVIII per kg of body weight, administered on a scheduled basis, usually every two to three days. For the treatment of acute bleeding episodes, the dose frequency is accelerated, with repeat infusions typically given every 8 to 24 hours depending on the required target FVIII activity level.

Administration and Procedural Rules

The infusion process requires specific control. Administration must proceed slowly, and the infusion rate must not exceed 2 mL per minute to ensure proper delivery. The dosing guidelines established for adults, including the weight-based calculation principle, apply equally to pediatric patients. Furthermore, the frequency and duration of use are guided primarily by laboratory monitoring of the patient’s FVIII activity levels. The treatment pattern distinguishes between long-term prophylaxis and short-term episodic use, with duration continuing until the specific clinical goal is achieved, such as for a minimum of seven days following major surgery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Иммунат

This overview describes the types of scientific research and clinical studies that have been conducted for this type of medication, focusing on how researchers examined its use and what the evidence suggests about the study landscape. It does not provide medical advice or instructions on how to use the medicine.


Research Evidence for Bleeding Episode Management

The core research for this medication was studied for its role as a clotting factor replacement. This research includes Phase III clinical trials, as well as large-scale observational settings using patient registries that gather data over many years of typical clinical use.

These studies were evaluated in populations with Hemophilia A, where the goal was observed in addressing the lack of clotting Factor VIII. Research examined both the use of the concentrate to treat episodic or acute changes (meaning when a bleed occurs) and its use in a routine preventive approach, known as prophylaxis. The main outcomes research monitored included measurements of hemostatic efficacy (how the stopping of a bleed was rated) and tracked the annualized bleeding rate (ABR) during routine preventive use.

Factor VIII replacement therapy as a class is documented in the broader evidence landscape for its primary use. However, comparative evidence is lacking between all individual Factor VIII products. Furthermore, some studies assessing outcomes related to episodic or acute changes rely on subjective rating scales, which means the interpretation of findings may vary across reports.


Research on Immunogenicity and Inhibitor Development

A key area of research for plasma-derived concentrates like Иммунат, which contain Von Willebrand Factor (VWF), was studied for its potential influence on the immune system's reaction to the therapeutic Factor VIII protein. This medication was evaluated in studies exploring the development of Factor VIII inhibitors, which is a complication where the body develops an immune response to the therapeutic protein.

Research examined this question primarily through randomized controlled trials (RCTs) and large, international cohort studies (registries) that monitored different types of Factor VIII products. The central measurement was the incidence of inhibitor development—the rate at which patients developed these antibodies. Studies monitored this incidence particularly in young children who were observed in conditions characterized by periods of heightened symptoms (severe Hemophilia A).

Studies in Previously Untreated Patients (PUPs)

Research focusing on previously untreated patients (PUPs)—patients who are receiving Factor VIII for the first time—is crucial because they are the group at the highest risk for inhibitor development. RCTs explored how the rate of inhibitor development was associated with the type of Factor VIII concentrate used (plasma-derived with VWF versus recombinant products). Findings were mixed across different global studies and subsequent analyses. While certain trials reported specific patterns related to the VWF-containing products, overall regulatory reviews have reported that evidence quality varies and the certainty of a definitive difference in inhibitor risk between the product classes remains low due to inconsistent results and other complicating factors.

Key Studies & References

  1. WHO Model List of Essential Medicines (22nd List, 2021)
  2. F8 gene: MedlinePlus Genetics (National Institutes of Health)

Frequently Asked Questions (FAQ)

Common questions about Иммунат (FAQ)


Q: How is Иммунат different from general vitamins or supplements?

Иммунат is a highly specialized biological medicine and a plasma-derived Coagulation Factor Product used to replace specific missing clotting proteins. According to official product information, it is formally classified as a biologic drug, distinguishing it from general vitamins or dietary supplements.


Q: Does Иммунат work right away, or does it take time?

Regulatory documents state that following the intravenous (IV) injection, the medicine causes a rapid increase in the plasma activity of Factor VIII, which is the clotting protein it replaces. This rapid rise in activity describes how the Factor VIII level is quickly supplemented in the bloodstream.


Q: Are there any long-term side effects noted for Иммунат?

A key long-term safety concern for this class of medicine is the potential development of inhibitor antibodies (neutralizing antibodies) to Factor VIII. This immune response can potentially compromise treatment effectiveness over time, especially in patients who have not been previously treated. Official guidelines state that regular laboratory monitoring is a required procedure used to assess this potential risk.


Q: Does Иммунат interact with common pain relievers?

Official regulatory labels generally do not list specific interactions between this medicine and common medications like pain relievers. Regulatory information notes that co-administered medicines should be reviewed by a healthcare professional, as some drugs may affect the clotting system.


Q: Can Иммунат be taken with antibiotics?

Specific constraints regarding the use of Иммунат with broad medication classes like antibiotics are generally not listed in official regulatory documents. Official documentation indicates that a healthcare professional must review all co-administered medications, including antibiotics, as part of the overall treatment plan.


Q: Does Иммунат contain any allergens like gluten or lactose?

The list of excipients (inactive ingredients) found on the official product label does not typically include common allergens such as gluten or lactose. Individuals with known allergies are advised to have the complete ingredient list (excipients) reviewed by a physician.


Q: How long does the effect of Иммунат usually last after stopping treatment?

Studies on the pharmacokinetic properties indicate that the active therapeutic component (Factor VIII) of traditional concentrates has a mean terminal half-life of approximately 12 hours. This means that after a single infusion, the Factor VIII level gradually decreases over about half a day, though the exact duration can vary widely between individuals.


Q: Can Иммунат be taken at the same time as cold and flu medicine?

The official product information states that Иммунат must not be mixed with other medicinal products or administered in the same infusion set. Any co-administration must be managed by the treating healthcare professional.


Q: What common supplements are listed as having a potential interaction with Иммунат?

Official regulatory labels generally do not list specific interactions with common dietary supplements. Official guidance indicates that a healthcare professional should be informed of all supplements being taken.


Q: Where is the official source for the prescribing information for Иммунат?

The official prescribing information (or Product Information/SmPC) is published and maintained by national regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These governmental bodies provide the authoritative, full details of the medicine's use.


Q: Is it necessary to finish the entire course of Иммунат as prescribed?

Official documentation indicates that treatment duration is calculated to achieve and maintain specific Factor VIII activity levels for a targeted clinical goal, such as healing after major surgery. Adherence to the prescribed duration is required to maintain the intended Factor VIII levels and support the therapeutic goal.


Q: Why do some people experience mild fatigue after starting Иммунат?

Official adverse reaction listings sometimes include general symptoms such as unusual tiredness or weakness (fatigue). Fatigue may also be a symptom of the underlying bleeding disorder itself or a complication like hemolysis (red blood cell breakdown). If this occurs, it is noted as a situation where medical evaluation may be necessary.


Q: Can Иммунат cause stomach upset, and is that normal?

Nausea and vomiting are listed as potential, though often less common, side effects in the official adverse reaction documents. Severe or persistent upset, particularly severe stomach pain, is documented as a possible sign of a serious allergic reaction, which requires medical review.


Q: Is a slight headache a known side effect of Иммунат?

Official regulatory documents indicate that headache is listed as one of the common adverse reactions for this class of medicine. Like other side effects, a headache can also be an early symptom of a hypersensitivity reaction. Any persistent or severe headaches are situations that should be reviewed by a healthcare provider.


Q: Are there any known food or drink restrictions when taking Иммунат?

The regulatory documents primarily focus on drug-drug interactions. While there are generally no specific food restrictions documented, official labeling advises that the use of alcohol or tobacco during treatment is a topic for discussion with a healthcare professional.


Q: If I miss a day of Иммунат, what happens?

Regulatory information notes a principle of management when a prophylactic dose is missed, which involves taking the dose promptly and then continuing the regular schedule as directed. Official documents specifically advise against doubling the next dose to compensate for the missed administration.


Q: What should I do if I feel dizzy after taking Иммунат?

Dizziness is a documented adverse reaction. If the dizziness is severe, sudden, or accompanied by other symptoms like fast heartbeat or chest tightness, official documents note this may be a sign of a serious hypersensitivity or vasomotor reaction that should be immediately evaluated by a healthcare provider.


Q: What makes Иммунат a prescription-only drug (if applicable)?

It is a biological product requiring individualized dosing based on laboratory monitoring and is intended for intravenous administration, which must be performed under the supervision of a healthcare professional.


Q: How does Иммунат affect general energy levels?

Unusual tiredness or weakness is listed as a possible side effect. Lack of energy can also be a symptom of the underlying bleeding disorder or subsequent complications like anemia, and is an observation that warrants review by a healthcare professional.


Q: Does Иммунат affect fertility or reproductive health?

Use during pregnancy and breastfeeding is generally not recommended due to limited or unavailable safety data. The decision for use during pregnancy or breastfeeding is based on an assessment of individual benefit versus risk.


Q: Is it safe to drive or operate machinery while using Иммунат?

Since adverse reactions such as dizziness or lightheadedness are documented, official information indicates that the ability to drive or operate machinery may be temporarily impaired. Because of the possibility of such adverse reactions, patients are advised that caution may be necessary when driving or operating machinery, particularly following an infusion.

How should Иммунат be stored and disposed of?

The storage and disposal of Immunate S/D (Human Coagulation Factor VIII/VWF) must strictly adhere to the conditions mandated by regulatory labeling to maintain product stability and integrity.


Storage Conditions

Condition Requirement
Temperature Store unopened vials in a refrigerator between 2 C and 8 C (36 F and 46 F). Do not freeze.
Protection Store in the original outer carton to protect the contents from light.
Stability The reconstituted solution must be used immediately or within the short time limit specified on the label (e.g., 1–3 hours). The solution must not be returned to the refrigerator.
Child Safety The product must be kept out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. The medicine must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Иммунат found in:

A-Z Index: